Lena van der Wekken-Pas

Lena van der Wekken-Pas

Auto-generated profile, based on publicly available information

Lena van der Wekken-Pas

Department of Pharmacy, Pharmacology and Toxicology, Radboudumc , Nijmegen

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
LWLena van der Wekken-Pas
Lena van der Wekken-Pas
FWFabian Weiss
Fabian Weiss
CSCharlotte Simon-Zuber
Charlotte Simon-Zuber
RSRena Sebisch
Rena Sebisch
CWCarmen Wiese
Carmen Wiese
ACAngela Colbers
Angela Colbers
This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%–75% lower. No virologic failure or vertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly long-acting injectable CAB/RPV may not be suitable for pregnant women, and monitoring of exposed infants is warranted.

9 November 2022 in Therapeutic Drug Monitoring
Verified
Journal Article
Open access
LWLena C. van der Wekken-Pas
Lena C. van der Wekken-Pas
JTJ.E.E. Totté
J.E.E. Totté
FLF. Verduyn Lunel
F. Verduyn Lunel
AZArjan van Zuilen
Arjan van Zuilen
MLMatthijs van Luin
Matthijs van Luin
Background: Cytomegalovirus causes morbidity and mortality, especially in immunocompromised patients, and is treated with (val)ganciclovir. Therapeutic drug monitoring of ganciclovir is often performed; however, clinically established target trough levels corresponding to efficacy are lacking. In 2021, our clinic increased the target trough level for ganciclovir from 1 to 2 mg/L to 2–4 mg/L. This study aims to compare both target trough levels in efficacy, toxicity, and occurrence of resistance. Methods: A retrospective cohort study was performed in adult solid organ recipients treated for cytomegalovirus infection with (val)ganciclovir. Clinical efficacy was defined as the absence of treatment failure, defined as > 1 log10 increase in viral load within 2 weeks of treatment initiation, therapy switch to foscarnet, and/or request for resistance analysis. Results: A total of 46 patients were involved in the study, with 200 ganciclovir trough levels obtained. The composite endpoint was recorded in 23 (69.7%) and 10 (76.9%) patients in the 1–2 mg/L and the 2–4 mg/L group, respectively (P = 0.18). No association was found between ganciclovir trough levels and the composite endpoint (P = 1.0). However, a correlation was found between ganciclovir trough levels and the occurrence of lymphopenia (P = 0.02). Conclusions: Our study could not establish a difference in clinical efficacy or toxicity between target trough levels of 1–2 mg/L or 2–4 mg/L because of the lack of clinical differences between the compared groups. However, a correlation was found between ganciclovir trough levels and lymphopenia, which warrants further investigation.

6 March 2024 in AIDS
Verified
Journal Article
Open access
LWLena van der Wekken-Pas
Lena van der Wekken-Pas
SNSylvia Nassiwa
Sylvia Nassiwa
TMThokozile Malaba
Thokozile Malaba
MLMohammed Lamorde
Mohammed Lamorde
LMLandon Myer
Landon Myer
ACAngela Colbers
Angela Colbers
Background: Both dolutegravir and efavirenz are known to be effective in pregnancy and postpartum to prevent vertical transmission of HIV and to maintain maternal health. Both drugs have also been associated with neuropsychiatric symptoms. To what extent, these symptoms occur in pregnant and postpartum women, however, is not yet known. Methods: This was a secondary analysis of the DolPHIN2 study, a multicentre randomized trial among women presenting late in pregnancy with untreated HIV – who received either a dolutegravir-containing or efavirenz-containing regimen. Longitudinal measures of depression, anxiety and sleep quality were analysed during pregnancy and up to 48 weeks postpartum. Results: Among 268 women, median (IQR) Edinburgh Post Natal Depression Score (EPDS) scores were 8 (3–11) and highest at enrolment. In the dolutegravir and efavirenz arm, respectively, 23.7 and 25.6% had an EPDS score above 9, indicating possible or probable depression. Abnormal Hospital Anxiety Depression scores (HADS) (above 11) were seen at least once during follow-up in 42 of patients (15.7%), although no differences were seen between treatment arms. No association was found between EPDS, suicidality and HADS scores and the assigned regimen (P = 0.93, 0.97 and 0.18 respectively). Median (IQR) Pittsburgh Sleep Quality index (PSQI) scores for dolutegravir and efavirenz were 6 (5–7) and 5 (5–6.5), respectively, P = 0.70. Conclusion: No statistically significant differences were observed between efavirenz-containing or dolutegravir-containing regimens. Rates of depression were high, but decreased over the course of time and confirm the need for psychological support after initial HIV diagnosis in pregnancy.

23 November 2021 in European Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
LWLc van der Wekken-Pas
Lc van der Wekken-Pas
PHPj de Haas
Pj de Haas
RWR Wisse
R Wisse
MRM Rados
M Rados
KEKcm van der Elst
Kcm van der Elst
To evaluate treatment options for candida keratitis and endopthalmitis after corneal transplantation. Case reports and literature review. Two patients with keratitis due to Candida glabrata/parapsilosis after corneal transplantation were successfully treated with a combination of topical voriconazole, intracameral voriconazole and amphotericin B, and systemic treatment with flucytosine. Natamycine and voriconazole topically are preferred therapeutic options for the treatment of fungal keratitis. Systemic flucytosine is a useful alternative additive, particularly for countries where natamycine is not registered as a pharmaceutical agent.

6 November 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
LWLena van der Wekken‐Pas
Lena van der Wekken‐Pas
DBDavid Burger
David Burger
RGRick Greupink
Rick Greupink
ACAngela Colbers
Angela Colbers
Aims: To determine breastmilk concentrations of doravirine via PBPK modelling in combination with a clinical lactation study. As women living with HIV are not able to cease antiretroviral therapy during lactation, it is necessary to establish drug transfer into breastmilk to determine exposure of the infant to antiretroviral drugs and potential risk of drug‐induced toxicity. Methods: PBPK modelling was performed with Simcyp v22 with the lactation module as an add‐on. Model predictions were compared with observed data, and model performance was considered adequate if predicted: observed ratios for AUC 0–24 , C max and half‐life fell between 0.7 and 1.43. Observed data originated from a study performed in healthy, lactating women from whom a full pharmacokinetic curve over 24 h was obtained in both plasma and breastmilk after a single dose of 100 mg doravirine. Concentrations were measured using validated LC–MS/MS assays. Noncompartmental analysis was performed within Phoenix Winnonlin. Results: The lactation model predicted a geometric mean (CV%) breastmilk to maternal plasma ratio of 0.39, 20 whereas it was 0.26 21 in the clinical part of the study. The median (IQR) predicted and observed daily infant dose based on an estimated breastmilk intake of 150 mL/day was 0.18 (0.12–0.29) and 0.18 (0.15–0.26) mg/day. The relative infant dose based on an estimated intake of 150 mL/day was predicted to be 2.27 (1.31–3.94)% and was 1.90 (1.50–2.44) % in the clinical part of the study. Conclusions: We present in silico and clinical evidence of the transfer of doravirine into breastmilk. However, based on these data, the infant's exposure to doravirine through breastmilk is not expected to be hazardous.

20 July 2025 in Journal of Chromatography B
Verified
Journal Article
Open access
LPL.C. van der Wekken - Pas
L.C. van der Wekken - Pas
EKE.W.J. van Ewijk - Beneken Kolmer
E.W.J. van Ewijk - Beneken Kolmer
LBL.H.M. Te Brake
L.H.M. Te Brake
DBD.M. Burger
D.M. Burger
With the use of newer and more robust antiretrovirals, the risk of viral transmission through breastfeeding has sharply diminished. This has led to a change in guideline recommendations. Currently, breastfeeding is regarded as an equipoise of formula, in case of a well-controlled HIV infection. However, it is not yet fully established whether infant exposure to antiretroviral drugs through breastmilk is a reason for concern. Only sparse and heterogenous data exist on concentrations of dolutegravir, raltegravir, bictegravir and doravirine in breastmilk. So further research is required and to accurately describe infant exposure of antiretrovirals through breastmilk, reproducible bioanalytical methods are needed. Our existing UPLC-MS/MS method for several anti-HIV drugs in EDTA-plasma was modified for validation of dolutegravir, bictegravir, raltegravir and doravirine concentrations in human breastmilk. [13C,2H5]-Dolutegravir, [13C,2H2,15N]-bictegravir, [2H6]-raltegravir and [13C6]-doravirine were used as internal standard. The sample preparation involved protein precipitation and detection was performed with tandem mass spectrometry (MS/MS) in a total runtime of 10 min. The assay was validated over the concentration range of 0.0100-10.0 mg/L for dolutegravir and doravirine, 0.00500-10.0 mg/L for raltegravir and 0.0200-20.0 mg/L for bictegravir. Within-run and between-run accuracy were within ±10 % of the nominal concentration and precision <10 CV% for quality controls at high, medium and low concentrations, and ± 8.8 % and < 14 CV%, respectively, at the lower limit of quantification for all analytes. Extraction recovery was 81 % and 79 % for dolutegravir and its internal standard, 83 % and 83 % for bictegravir and its internal standard, 89 % and 92 % for raltegravir and its internal standard and 104 % and 101 % for doravirine and its internal standard. Processed samples of dolutegravir, bictegravir, raltegravir and doravirine in breastmilk were 108 %, 95.5 %, 105 % and 102 % after 14 days at 4 °C. The assay is currently being implemented successfully in pharmacokinetic studies.